 |
|
|
| |
EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR +/- RBV FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV G1, G4 OR G6 INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/RBV: C-EDGE TREATMENT-EXPERIENCED
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna, Austria
Paul Kwo1, Ed Gane2, Cheng-Yuan Peng3, Brian Pearlman4, John Vierling5, Lawrence Serfaty6, Maria Buti7, Stephen Shafran8, Paul Stryszak9, Li Lin9, Jacqueline Gress9, Michael Robertson9, Janice Wahl9, Eliav Barr9, Barbara Haber9
1Indiana University, Indianapolis, IN, USA; 2Auckland Clinical Studies, Grafton, Auckland, New Zealand; 3China Medical University Hospital, Taichung, Taiwan; 4Center for Hepatitis C, Atlanta Medical Center, Atlanta, GA, USA; 5Baylor College of Medicine, Baylor-St. Luke's Medical Center, Houston, TX, USA; 6Service d'Hépatologie, Hôpital Saint-Antoine, APHP, UPMC Paris 6, Paris, France; 7Hospital General Universitari Vall d'Hebron, Barcelona, Spain; 8University of Alberta, Edmonton, Alberta, Canada; 9Merck & Co. Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
